Charles River Laboratories earnings beat by $0.12, revenue topped estimates

Charles River Laboratories (CRL) reported Q3 2026 results with 4.7% organic revenue growth and non-GAAP EPS of $3.09, beating estimates. Despite this, shares fell 5.88% due to concerns over margin sustainability and delayed pricing power recovery. Revenue was $982.7M, with non-GAAP operating margin expanding to 23.0%. The DSA segment saw 5.9% organic growth, while Manufacturing grew 7.4% organically. Management expects pricing benefits to materialize in late 2027.

Charles River Laboratories reported Q3 2026 revenue of $982.73M, down 2.2% YoY, while net income rose to $333.07M and EPS increased to $6.86. Management cited improving demand in Discovery and Safety Assessment, portfolio changes, and cost savings. Nine-month revenue declined 1.3%, with growth in microbial testing and China model sales. The company completed divestitures and acquisitions, targeting $300M in annual savings by 2026.

Charles River Laboratories (CRL) reported adjusted Q3 earnings of $3.09 per share, beating estimates of $2.97, with revenue of $982.7M, also above expectations. Despite the beat, the stock dropped. The company earned $2.43 per share on $1.01B in the same period last year.

Charles River Laboratories (CRL) raised its 2026 outlook, expecting revenue to decline 1.5%-2.0% (previously 2.5%-3.5%) and organic revenue to grow at least 1.5% (previously 0%-1%). EPS estimates increased to $8.15-$8.35 from $3.05-$3.35, with non-GAAP EPS at $11.35-$11.55. Q3 profit rose to $333.07M ($6.86/share) due to a $245.6M tax benefit, while revenue fell 2.1% to $982.732M. Shares dropped nearly 4% in pre-market trading.

Charles River Laboratories (CRL) reported Q3 net income of $333.1M, or $6.86 per share. Adjusted earnings were $3.09 per share, exceeding analyst estimates of $2.98 per share. Revenue was $982.7M, surpassing expectations of $956.8M. The company expects full-year earnings between $11.35 and $11.55 per share.

Charles River Laboratories reported Q3 2026 revenue of $982.7M, beating estimates by 2.3% and showing a 2.2% YoY decline. Adjusted EPS of $3.09 beat estimates by 4%. Management raised full-year adjusted EPS guidance to $11.45 at the midpoint. Operating and free cash flow margins improved YoY.